Clinical and Pathological Stage Discordance among 433,514 Breast Cancer Patients

ConclusionsAmong breast cancer patients, nearly one-third exhibit clinical-pathological stage discordance. This high likelihood of discordance is important to consider for counseling and treatment planning.
Source: The American Journal of Surgery - Category: Surgery Source Type: research

Related Links:

Cancers, Vol. 11, Pages 1242: The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2− Metastatic Breast Cancer: Biological Mechanisms and New Treatments Cancers doi: 10.3390/cancers11091242 Authors: Daniele Presti Erica Quaquarini Endocrine-based treatments are the normal standard-of-care in women with hormone receptor-positive/Human Epidermal growth factor Receptor 2-negative metastatic breast cancer. Despite the well-known efficacy of these drugs as first-line therapies, about 50% of women develop endocrine resistance and disease progression. The treatment of these patients has represented ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Publication date: Available online 15 August 2019Source: Carbohydrate PolymersAuthor(s): Yaping Wang, Junmin Qian, Ming Yang, Weijun Xu, Jinlei Wang, Guanghui Hou, Lijie Ji, Aili SuoAbstractCombination chemotherapy has attracted more and more attention in the field of anticancer treatment. Herein, a synergetic targeted combination chemotherapy of doxorubicin (DOX) and cisplatin in breast cancer was realized by HER2 antibody-decorated nanoparticles assembled from aldehyde hyaluronic acid (AHA) and hydroxyethyl chitosan (HECS). Cisplatin and DOX were successively conjugated onto AHA through chelation and Schiff’s base ...
Source: Carbohydrate Polymers - Category: Biomedical Science Source Type: research
Contributors : Alison Hirukawa ; William J MullerSeries Type : Expression profiling by arrayOrganism : Mus musculusMonoclonal antibodies (mAbs) targeting the oncogenic receptor tyrosine kinase ERBB2/HER2, such as Trastuzumab, are the standard of care therapy for breast cancers driven by ERBB2 overexpression and activation. However, a substantial proportion of patients exhibits de novo resistance. Here, by comparing matched Trastuzumab-na ïve and post-treatment patient samples from a neoadjuvant trial, we link resistance with elevation of H3K27me3, a repressive histone modification catalyzed by Polycomb Repressor Compl...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Mus musculus Source Type: research
Background HER2-positive advanced breast cancer (ABC) is associated with significant heterogeneity in long-term disease control and survival. Prognostic models for HER2-positive ABC patients considering first-line pertuzumab, trastuzumab and docetaxel have not been evaluated. Methods A pre-treatment prognostic model for progression-free survival (PFS) and overall survival (OS) was developed for HER2-positive ABC patients initiating first-line pertuzumab, trastuzumab and docetaxel using clinicopathological data from the randomised clinical trial CLEOPATRA (n=408). Cox proportional hazard analysis with a backwards deleti...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Authors: Md Pauzi SH, Saari HN, Roslan MR, Syed Khair Azman Jamalulil SNS, Tauan IS, Mohd Rusli FA, Aizuddin AN Abstract INTRODUCTION: Evaluation of HER2 status in breast cancer using immunohistochemistry (IHC) and in-situ-hybridisation (ISH) study is important to establish prognosis and to select patient for targeted therapy. OBJECTIVE: The study aims to determine the concordance between HER2 protein IHC score and its gene status by dual-colour dual-hapten in-situ-hybridization (DDISH) study. MATERIALS AND METHODS: Retrospective study was performed on 767 referred breast cancer cases over a period of five ...
Source: Malaysian Journal of Pathology - Category: Pathology Tags: Malays J Pathol Source Type: research
Publication date: Available online 20 August 2019Source: Academic RadiologyAuthor(s): Laura Heacock, Alana Lewin, Abimbola Ayoola, Melanie Moccaldi, James S. Babb, Sungheon G. Kim, Linda MoyRationale and ObjectivesPathologic complete response (pCR) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after HER2-targeted therapy correlates increased disease-free survival and decreased mastectomy rates. The aim of this study was to explore tumor shrinkage patterns and initial tumor enhancement with pCR in HER2-positive breast cancer.Materials and MethodsThis was an institutional review boar...
Source: Academic Radiology - Category: Radiology Source Type: research
Conditions:   Breast Cancer;   Solid Tumor Intervention:   Drug: OBT076, a CD205-directed antibody-drug conjugate Sponsor:   Oxford BioTherapeutics Ltd Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Future Oncology, Ahead of Print.
Source: Future Oncology - Category: Cancer & Oncology Authors: Source Type: research
Condition:   Metastatic Breast Cancer Intervention:   Drug: Nivolumab Sponsors:   Seoul National University Hospital;   Seoul National University Bundang Hospital;   Korean Cancer Study Group (KCSG);   Eisai Korea;   Ono pharmaceutical Korea Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS: This multicentric retrospective study confirmed that sequential adjuvant therapy with anthracycline-based chemotherapy and paclitaxel for HER2 negative breast cancer is an effective and reliable regimen. PMID: 31424664 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Surgery